Clinical trials: HCV, open to volunteers
HEPATITIS C (HCV), Hepatitis B Virus (HBV)
Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France
In Mongolia, mortality from hepatocellular carcinoma (HCC) is one of the highest in the world. Viral hepatitis is the main cause of HCC: the prevalence of hepatitis B (HBV) estimated at 11% In Mongolia, hepatitis C (HCV) at 8.5%…
- Conditions
- HEPATITIS C (HCV), Hepatitis B Virus (HBV), Hepatitis D, Hepatocellular Carcinoma (HCC)
- Trial name
- Mondelta (NCT07038863)
- Testing
- Community screening for hepatitis B, C and delta in the Mongolian population living in France
- Where
- 11 sites in France
- Volunteers
- 2,000 people
- Sponsor
- Hospices Civils de Lyon
Hepatitis C Virus, Mutation Abnormality
Genotype and Subtype Mapping of the Hepatitis C Virus
Chronic hepatitis C virus (HCV) infection is the second leading cause of primary liver cancer worldwide and the leading cause in the United States.
- Conditions
- Hepatitis C Virus, Mutation Abnormality, RNA Positive, Unusual Subtype
- Trial name
- CARTO-VHC (NCT07503288)
- Where
- France
- Volunteers
- 2,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatitis C, RDT
Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania
The goal of this non-randomised, quasi-experimental, prospective comparative trial is to trial simplified care pathways for hepatitis C testing and treatment for people who inject drugs in Armenia, Georgia, and Tanzania.
- Trial name
- CUTTS HepC (NCT06159504)
- Testing
- sofosbuvir/velpatasvir (SOF/VEL), Shortened read time of rapid diagnostic test for hepatitis C virus.
- Where
- Armenia
- Volunteers
- 3,040 people
- Sponsor
- Médecins du Monde
Cirrhosis, Cirrhosis Due to Hepatitis B
Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer
Aim: To use magnetic resonance imaging (MRI) scans without contrast to help improve diagnosis of liver cancer in people who are at increased risk of developing liver cancer.
- Conditions
- Cirrhosis, Cirrhosis Due to Hepatitis B, Cirrhosis and Chronic Liver Disease, Cirrhosis Due to Hepatitis C
- Trial name
- AMULET (NCT06658782)
- Testing
- non contrast enhanced MRI
- Where
- 2 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- University of Oxford
Hepatitis C
A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial)
The purpose of this study is to investigate the safety and antibody (germ fighters) response of the experimental (investigational) vaccine against HCV when injected into the arm of healthy adults.
- Trial name
- NCT07237282
- Testing
- AVIHepC1, Normal Saline
- Where
- 3 sites in Canada
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Chronic Hepatitis C Infection
HEPATITIS C SCREENING in ADULTS with RISK FACTORS in FIVE CITIES of COLOMBIA'S CARIBBEAN COAST (FIVE-CC)
Hepatitis C virus (HCV) infection is a significant cause of chronic hepatitis, cirrhosis, and liver cancer (1). The risk of developing cirrhosis in people with chronic HCV infection ranges between 15% and 30% over a period of 20…
- Trial name
- FIVE-CC (NCT06899542)
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Diana Rocio Chavez Bejarano
HIV, HBV (Hepatitis B Virus)
HIV/HBV/HCV Triple Screening in Primary Care
Design: This will be a within-subjects repeated-measures design, testing an electronic medical record pop-up alert linked to order panels for screening blood tests for human immunodeficiency virus (HIV), hepatitis B virus (HBV)…
- Conditions
- HIV, HBV (Hepatitis B Virus), HCV
- Trial name
- NCT07031219
- Testing
- electronic medical record alert linked to orders
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Texas Southwestern Medical Center
Liver Cirrhosis
A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia
This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.
- Trial name
- OP-724-H202 (NCT07681089)
- Testing
- Foscenvivint
- Where
- 4 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Kiminori Kimura, MD
Chronic Liver Disease and Cirrhosis, Liver Cancer
"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
Development of preclinical translational models for chronic liver tumors and diseases study, such as spheroids cultured in autologous medium and murine xenograft models to test the efficacy of new therapeutic strategies.
- Conditions
- Chronic Liver Disease and Cirrhosis, Liver Cancer, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
- Trial name
- LivMOD (NCT04690972)
- Testing
- Blood sample during surgery, Taking an additional biopsy, Blood sample during diagnostic test
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Hepatitis C Virus (HCV)
Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data
The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.
- Trial name
- NCT07419347
- Where
- 2 sites in Canada
- Volunteers
- 2,000 people
- Sponsor
- AbbVie
HIV, Hepatitis B
Pan-Viral Screening and Linkage to Care Among GBMSM and Trans Women in Spain
The World Health Organization (WHO) aims to eliminate viral hepatitis as a public health threat by 2030, with major reductions in hepatitis B and C incidence and mortality.
- Conditions
- HIV, Hepatitis B, Hepatitis C
- Trial name
- PAN-TESTATE (NCT07085715)
- Testing
- Online self-sampling testing strategy to enhance pan-viral testing (HBV, HCV, HIV)
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Fundació Institut Germans Trias i Pujol
Multiplex Testing of HIV, HBV, HCV and Syphilis, HIV
Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV/HBV/HCV/Syphilis)
Performance study to evaluate the clinical performance of the In-Vitro Diagnostics Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and…
- Conditions
- Multiplex Testing of HIV, HBV, HCV and Syphilis, HIV, HBV, HCV
- Trial name
- MAGICS IBCS (NCT07170748)
- Where
- 2 sites in Côte d’Ivoire, Kenya
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- MagIA Diagnostics
Liver Diseases, Humans
Liver Disease and Other Systemic Diseases
Examine the association of chronic liver diseases (including hepatitis B, hepatitis C, alcoholic liver disease, fatty liver, liver cirrhosis, and hepatocellular carcinoma) with other systemic diseases by retrospectively analyzing…
- Conditions
- Liver Diseases, Humans, Progression, Carcinogenesis
- Trial name
- NCT04525833
- Where
- Taiwan
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Cirrhosis, Cirrhosis, Liver
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
- Conditions
- Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B
- Trial name
- LCN RESCU (NCT05832229)
- Testing
- Rosuvastatin
- Where
- 13 sites in United States
- Volunteers
- 260 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HCV Infection, HCV Elimination
The Epidemic Status and Development Trend of Hepatitis C Virus Infection in Pregnant Women in Xi'an
The objectives of this study are to improve HCV linkage-to-care in Chinese women and provide theoretical basis for the scientific formulation of HCV prevention and control strategies for pregnant women.
- Trial name
- NCT06952036
- Testing
- Standard Direct-acting antivirals (DAA) treatment procedures for patients with hepatitis C
- Volunteers
- 200,000 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
HIV Prevention, Sexually Transmitted Infections (STI)
California MEPS Hub
The California Hub for HIV/SUD Prevention Research with Reentry Populations addresses the question: "Can the evidence-based MEPS intervention be adapted and implemented at a range of organizations to effectively serve a wider…
- Conditions
- HIV Prevention, Sexually Transmitted Infections (STI), Preexposure Prophylaxis (PrEP), Incarceration
- Trial name
- NCT07433985
- Testing
- Mobile Enhanced Prevention Support (MEPS), Control
- Where
- 3 sites in United States
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Patients Undergoing Routine Health Care, Heart Diseases
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
The purpose of this study is to collect DNA samples from patients undergoing routine care at the University of Chicago. These samples will be tested for differences in genes that may suggest greater risk of side effects or chance…
- Conditions
- Patients Undergoing Routine Health Care, Heart Diseases, Inflammatory Bowel Diseases, Autoimmune Disease
- Trial name
- NCT01280825
- Where
- United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Hepatitis C in Substance Users
Elimination of Hepatitis C Virus Among Users of Substances
Substance users are a vulnerable group that should be prioritized in HCV (Hepatitis C Virus) elimination efforts in Mexico and in which it is feasible to carry out micro-elimination programs.
- Trial name
- EHCUS (NCT05503979)
- Testing
- Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]
- Volunteers
- 1,000 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Hepatitis C Virus Infection
Characterization of Immune Genotypes and Antibody Profiles to Foster the discoVERY of diagnosticbioMARKERS of Liver Cancer Development
Hepatitis C virus (HCV), which infects more than 185 million people, is a major risk factor. Direct-acting antiviral (DAA) therapy has significantly improved the eradication of the virus, but has not completely eliminated the…
- Trial name
- VERYMARKERS (NCT06718530)
- Where
- 4 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
HCV
Facilitated Telemedicine in the Bassett Health System
Hepatitis C virus is a leading cause of morbidity and mortality globally with the highest prevalence and incidence among people with opioid use disorder.
- Trial name
- NCT06483451
- Volunteers
- 200 people
- Sponsor
- State University of New York at Buffalo